IMARC-Style Industry Analysis Reveals a CAGR of 18.62% During 2026–2034, with Products Segment Holding 68% Market Share in 2025

The United States Genomics Market is witnessing significant expansion as precision medicine adoption accelerates across healthcare systems and research institutions. Valued at USD 15.64 Billion in 2025, the market is projected to reach USD 72.75 Billion by 2034, growing at a robust CAGR of 18.62% during 2026–2034.

Growth is fueled by expanding applications in oncology diagnostics, rare disease identification, pharmacogenomics, and biomarker discovery. Major healthcare networks are integrating genomic testing into routine clinical workflows, while pharmaceutical and biotechnology companies increasingly leverage genomic data to optimize drug discovery pipelines. Government-backed initiatives such as the All of Us Research Program and the National Human Genome Research Institute (NHGRI) continue to strengthen national genomic databases, accelerating translation of genomic discoveries into clinical practice.

Access In-Depth Market Intelligence – Download Your Free Sample Copy: https://www.imarcgroup.com/united-states-genomics-market/requestsample

Key Market Statistics at a Glance

· Base Year: 2025
· Historical Years: 2020–2025
· Forecast Period: 2026–2034
· Market Size (2025): USD 15.64 Billion
· Projected Size (2034): USD 72.75 Billion
· Growth Rate: CAGR of 18.62%
· Leading Component: Products (68% share in 2025)
· Leading Technology: Sequencing (48% share in 2025)
· Leading Application: Biomarkers Discovery (26% share in 2025)
· Leading End User: Research Centers (36% share in 2025)

United States Genomics Market Growth Trends

• Expansion of Multiomics Integration in Research and Clinical Applications

The convergence of genomics with proteomics, transcriptomics, metabolomics, and epigenomics is enabling deeper biological insights and improved therapeutic target identification. Research institutions and pharmaceutical companies are increasingly adopting integrated multiomics platforms to accelerate precision medicine initiatives. Advanced sequencing technologies, spatial transcriptomics, and CRISPR-based tools are further strengthening genomic research capabilities across the United States.

• Rising Adoption of Liquid Biopsy for Non-Invasive Cancer Detection

Liquid biopsy technologies utilizing circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) analysis are transforming oncology diagnostics. Healthcare providers are increasingly implementing non-invasive genomic testing solutions for early cancer detection, treatment monitoring, and minimal residual disease assessment. This trend supports personalized treatment pathways and enhances patient comfort compared to traditional tissue biopsies.

• Artificial Intelligence Transforming Genomic Data Analysis

Artificial intelligence (AI) and machine learning (ML) platforms are revolutionizing genomic data interpretation. Advanced bioinformatics tools accelerate variant identification, enhance diagnostic accuracy, and streamline biomarker discovery processes. Cloud-based genomic analytics platforms are democratizing access to sophisticated analytical capabilities, enabling smaller laboratories and research institutions to adopt advanced genomic workflows efficiently.

Get Customized Segmentation Intelligence — Speak Directly to Our Expert:https://www.imarcgroup.com/request?type=report&id=20477&flag=C

United States Genomics Industry Segmentation

IMARC Group provides detailed segmentation analysis across component, technology, application, and end-user categories, with forecasts at regional and national levels for 2026–2034.

Analysis by Component

• Products — Leading Segment (68% Market Share in 2025)

The products segment dominates the United States genomics market, encompassing sequencing instruments, consumables, reagents, microarray platforms, and associated software solutions. Continuous technological advancements improving sequencing throughput, accuracy, and cost-efficiency are driving demand. Recurring consumption of reagents and consumables provides stable revenue streams supporting sustained market growth.

• Services

Includes core genomics services, NGS-based services, biomarker translation services, and computational services supporting research and clinical diagnostics.

Analysis by Technology

• Sequencing — Leading Technology (48% Market Share in 2025)

Next-generation sequencing (NGS) technologies lead the market due to expanding clinical applications in oncology, inherited disease testing, and population genomics. Improvements in long-read sequencing, single-cell analysis, and cost optimization are broadening accessibility across hospital systems and research laboratories.

• Microarray

• Polymerase Chain Reaction (PCR)

• Nucleic Acid Extraction and Purification

• Others

Analysis by Application

• Biomarkers Discovery — Largest Application (26% Market Share in 2025)

Biomarker discovery remains central to genomic innovation, supporting targeted therapy development and companion diagnostics. Pharmaceutical companies and research institutions leverage genomics to identify genetic variants and molecular signatures that guide personalized treatment strategies, particularly in oncology and rare diseases.

• Functional Genomics

• Epigenomics

• Pathway Analysis

• Others

Analysis by End User

• Research Centers — Leading End User (36% Market Share in 2025)

Research centers and government-funded institutions represent the largest end-user segment, driven by strong federal funding and advanced research infrastructure. Academic institutions and national genome centers conduct large-scale sequencing initiatives supporting drug discovery, disease research, and population genomics programs.

• Hospitals and Clinics

• Pharmaceutical and Biotechnology Companies

• Others

Regional Insights: United States Genomics Ecosystem

The United States maintains global leadership in genomics, supported by world-class research infrastructure, federal funding programs, and strong public-private partnerships.

• Northeast: Anchored by leading academic and medical research institutions driving innovation in clinical genomics and precision medicine.
• Midwest: Expanding genomic capabilities through research universities and integrated healthcare networks.
• South: Growing biopharmaceutical presence and medical research hubs strengthening genomic testing adoption.
• West: Home to major sequencing technology developers and biotechnology clusters accelerating AI-driven genomics innovation.

Market Dynamics

Growth Drivers

Expanding Precision Medicine Adoption

Healthcare systems increasingly integrate genomic testing into oncology diagnostics, pharmacogenomics, and inherited disease screening. Precision medicine initiatives are enabling personalized therapeutic strategies that improve treatment outcomes and reduce adverse drug reactions.

Strong Government Funding and Research Support

Federal programs and NIH-backed initiatives continue funding genome sequencing projects, workforce development, and clinical translation efforts, strengthening national genomics infrastructure.

Technological Innovation and Cost Reduction

Advancements in sequencing chemistry, long-read technologies, AI-driven analytics, and cloud computing are reducing per-genome costs and improving scalability, enabling broader adoption across clinical and research settings.

Market Restraints

Data Privacy and Security Concerns

Rising cybersecurity threats and strict regulatory requirements surrounding genetic data protection create compliance complexities and operational costs for healthcare organizations.

Reimbursement Challenges

Variable insurance coverage for emerging genomic applications limits broader clinical adoption, particularly for novel testing services lacking established cost-effectiveness evidence.

Skilled Workforce Shortages

Growing demand for bioinformatics specialists, genetic counselors, and genomic data analysts outpaces supply, constraining scalability and operational efficiency.

Competitive Landscape

The United States genomics market demonstrates moderate to high competitive intensity. Established multinational corporations maintain strong positions in sequencing platforms, while innovative biotechnology startups focus on niche applications and AI-powered genomic analytics. Market participants emphasize technological innovation, strategic partnerships with healthcare systems, and portfolio expansion across multiomics solutions to enhance competitive positioning.

Recent Developments

• February 2025: Foundation Medicine announced plans to launch new germline testing solutions, FoundationOne Germline and FoundationOne Germline More, in the United States to identify hereditary cancer-related genetic variants.

• July 2024: Thermo Fisher Scientific partnered with the National Cancer Institute on the myeloMATCH precision medicine trial utilizing next-generation sequencing technology to match patients with biomarker-driven clinical trials across North America.

Future Scope: What Lies Ahead for the United States Genomics Market?

• AI-powered genomic interpretation enhancing diagnostic precision
• Rapid expansion of liquid biopsy applications
• Growth in long-read sequencing and single-cell analysis technologies
• Increased integration of genomics into routine healthcare protocols
• Expansion of multiomics platforms accelerating drug discovery pipelines

The market generated USD 15.64 Billion in 2025 and is projected to reach USD 72.75 Billion by 2034, growing at a CAGR of 18.62% during 2026–2034, underscoring strong long-term growth potential supported by innovation, federal funding, and expanding clinical adoption of precision medicine.

Unlock Complete Market Intelligence — Access the Full Report Today: https://www.imarcgroup.com/united-states-genomics-market

Frequently Asked Questions (FAQ)

1. What is the current size of the United States genomics market?
The market was valued at USD 15.64 Billion in 2025.

2. What is the projected value by 2034?
It is expected to reach USD 72.75 Billion by 2034.

3. What is the expected CAGR?
The market is projected to grow at a CAGR of 18.62% during 2026–2034.

4. Which segment leads the market?
The products segment leads with a 68% share in 2025.

5. What are the key growth drivers?
Major drivers include precision medicine adoption, AI integration, federal funding, technological advancements in sequencing, and expanding biomarker discovery applications.

About IMARC Group

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives across healthcare, technology, chemicals, agriculture, and other industries.

Media & Sales Contact

IMARC Group
Email: sales@imarcgroup.com
United States: +1-201-971-6302
India: +91-120-433-0800
United Kingdom: +44-753-714-6104